Oncotarget

Research Perspectives:

YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention

Alastair H. Davies and Sandra E. Dunn _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2011; 2:401-406. https://doi.org/10.18632/oncotarget.276

Metrics: PDF 2029 views  |   HTML 2847 views  |   ?  


Abstract

Alastair H. Davies and Sandra E. Dunn

1Laboratory of Oncogenomic Research, Departments of Pediatrics and Experimental Medicine, Child and Family Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada

Keywords: YB-1, HER2, RSK, MAPK signaling, pre-malignancy, Kinex antibody microarray

Received: April 21, 2011; Accepted: May 13, 2011; Published: May 13, 2011;

Correspondence:

Sandra E. Dunn, e-mail:

Abstract

Surprisingly little is known about the underlying genetic events that trigger the progression of a normal cell into a cancerous cell. We recently developed a YB-1-driven model of pre-malignancy where we uncovered that the oncogene promotes genomic instability through cell cycle checkpoint slippage and centrosome amplification. In this research perspective, we describe a possible mechanism by which YB-1 instigates preneoplastic transformation. Using Kinex antibody microarrays with coverage of 800 proteins, we discovered that pre-malignant cells exhibit deregulated signal transduction along the HER2-MAPK-RSK axis. We will discuss the implications of these finding in regard to early intervention strategies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 276